Plus   Neg

BT Group H1 Pre-tax Profit Down 20%; Lifts Low End Of FY Adj. EBITDA Outlook Range

Telecom company BT Group plc (BT_A.L,BT) reported Thursday that its first-half profit before tax was 1.06 billion pounds, down 20 percent from 1.33 billion pounds in the year-ago period.

Profit after tax also fell 20 percent to 856 million pounds from 1.068 billion pounds a year ago. Basic earnings per share declined to 8.6 pence from 10.8 pence last year.

Adjusted EBITDA was 3.72 billion pounds, down 5 percent from 3.92 billion pounds in the prior-year period due to lower revenues, partly offset by sports rights rebates, savings from the company's modernisation programme and other cost initiatives including Covid-19 mitigating actions.

Revenue for the quarter declined 8 percent to 10.59 billion pounds from 11.47 billion pounds last year. The decline in revenue was primarily due to the impact of Covid-19, including reduced BT Sport revenue and a reduction in business activity in the company's enterprise units, and declines in legacy products.

The company said that no interim dividend has been declared for the current year.

Looking ahead, BT Group raised the lower end of its adjusted EBITDA outlook range for fiscal 2020/21 to 7.3 billion pounds. The revised outlook range is now 7.3 billion pounds to 7.5 billion pounds, compared to the prior outlook range of 7.2 billion to 7.5 billion pounds.

The company projects adjusted EBITDA of at least 7.9 billion pounds for fiscal 2022/23. The company noted that the growth in EBITDA underpins the planned reinstatement of its dividend next year, while ensuring it can continue to drive value-creating investments in its networks and products.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT